Prices for new US drugs doubled in 4 years as focus on rare disease grows#Prices #drugs…
Tag: disease
Pasithea's PAS-004 shows promise in inflammatory disease study
Pasithea's PAS-004 shows promise in inflammatory disease study#Pasithea039s #PAS004 #shows #promise #inflammatory #disease #study
WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA
WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for…
First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson's disease
First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson's disease#patients…
J&J's skin disease drug meets main goal in late-stage study
J&J's skin disease drug meets main goal in late-stage study#JampJ039s #skin #disease #drug #meets #main #goal…
Redx Pharma's RXC008 shows promise in Phase 1 trial for Crohn's disease
Redx Pharma's RXC008 shows promise in Phase 1 trial for Crohn's disease#Redx #Pharma039s #RXC008 #shows #promise…
Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities
Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities #Mirum #Pharmaceuticals #Respectable #Liver #Rare…
UniQure N.V. (QURE) Soars on FDA Breakthrough Therapy Designation for Huntington’s Disease Treatment
As of this writing, UniQure N.V.’s stock price has surged 35.89% to $12.79 per share after…
Verve Therapeutics: A New Era in Cardiovascular Disease Treatment?
In a major breakthrough, Verve Therapeutics (VERV) has announced positive results from its Heart-2 clinical trial.…
Anavex: A Small Bit Of Progress Against Alzheimer's Disease
Anavex: A Small Bit Of Progress Against Alzheimer's Disease #Anavex #Small #Bit #Progress #Alzheimer039s #Disease
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension…
NeOnc Technologies Holdings: New IPO gets a Rare Pediatric Disease Designation and a 37.92% Jump in the Market
In today’s fast-paced biotech landscape, it takes more than just innovative technology to make waves –…
Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial
Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial#Experimental #Lilly #drug #cuts…
Soleno Therapeutics: A Breakthrough in Rare Disease Treatment
The biotech world is buzzing with excitement as Soleno Therapeutics (SLNO) has just received FDA approval…
Ireland adopts Maven for disease surveillance
Ireland adopts Maven for disease surveillance#Ireland #adopts #Maven #disease #surveillance
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease#Development #Prediction #Model…
Tenaya Therapeutics: TN-201 Isn't The Only Shot On Goal Targeting Heart Disease
Tenaya Therapeutics: TN-201 Isn't The Only Shot On Goal Targeting Heart Disease #Tenaya #Therapeutics #TN201 #Isn039t…
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
PADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory…